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Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than
5 million deaths worldwide. Multiple reports indicate that the endothelium is involved
during SARS-Cov-2-related disease (COVID-19). Indeed, COVID-19 patients display
increased thrombophilia with arterial and venous embolism and lung microcapillary
thrombotic disease as major determinants of deaths. The pathophysiology of endothelial
dysfunction in COVID-19 is not completely understood. We have investigated the role
of subunit 1 of the SARS-CoV-2 spike protein (S1SP) in eliciting endothelial barrier
dysfunction, characterized dose and time relationships, and tested the hypothesis
that heat shock protein 90 (HSP90) inhibitors would prevent and repair such injury.
S1SP activated (phosphorylated) IKBα, STAT3, and AKT and reduced the expression of
intercellular junctional proteins, occludin, and VE-cadherin. HSP90 inhibitors (AT13387
and AUY-922) prevented endothelial barrier dysfunction and hyperpermeability and
reduced IKBα and AKT activation. These two inhibitors also blocked S1SP-mediated
barrier dysfunction and loss of VE-cadherin. These data suggest that spike protein
subunit 1 can elicit, by itself, direct injury to the endothelium and suggest a role of
HSP90 inhibitors in preserving endothelial functionality.
Keywords: SARS-CoV-2, spike protein, endothelial dysfunction, heat shock proteins, HSP90 inhibitors, AUY-922,
AT13387

INTRODUCTION
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for the 2020
pandemic, has infected more than 250,000,000 people and provoked the deaths of more than 5
million people worldwide (John Hopkins Coronavirus Resource Center)1 . SARS-CoV-2 enters the
cell through its surface spike protein (SP) that binds the angiotensin-converting enzyme-2 (ACE2)
expressed on alveolar type II and endothelial cells (Kumar et al., 2020; Zamorano Cuervo and
Grandvaux, 2020). Multiple reports have underlined the contribution of endothelial dysfunction
1
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in SARS-CoV-2-related disease (COVID-19) (Lei et al., 2021).
Indeed, COVID-19 patients display high rates of pulmonary
embolism, thrombosis, and disseminated intravascular
coagulopathy (Gando et al., 2016; Santulli, 2016, 2018), all
mortality predictors in the critically ill, infected patients
(Walborn et al., 2019).
The SARS-CoV-2 SP shares about 76 and 97% of amino acid
identities with SARS-CoV and the bat coronavirus, RaTG13, with
the receptor-binding domain (RBD) having about 74% and 90.1%
homology, respectively. SP exists in trimers on the virus surface,
with an average expression of ∼96 trimers per virus particle
(Ke et al., 2020). SPs are typical class I viral fusion proteins
that require protease cleavage for the activation of their fusion
potential (Ou et al., 2016).
The ∼180 kDa SP contains two subunits, namely, S1
(∼75 kDa) and S2 (∼100 kDa), that mediate attachment and
membrane fusion, respectively. The S1 C- and N-terminal
domains fold as two independent domains, and even though
the C-domain preferentially binds ACE2, both can serve as RBD
(Li et al., 2005). Cleavage of the SP occurs in two steps: first, a
cleavage between S1 and S2 followed by a second S2 cleavage.
This process is mediated by different host proteases, such as furin,
trypsin, cathepsin, transmembrane protease serine protease-2
(TMPRSS-2), TMPRSS-4, PIK5, TPC2, cathepsin L, or human
airway trypsin-like protease (HAT) (Bertram et al., 2011, 2013;
Gierer et al., 2013; Millet and Whittaker, 2014). Once SP is
cleaved, the S2 binds ACE2 and promotes the fusion of the
viral membrane to the host cell and the subsequent release of
genetic material (Walls et al., 2020). Up to 45% of the cleaved
subunit 1 (S1SP) is released as a peptide in the extracellular or
vascular compartment (Ke et al., 2020). Little is known about
the contribution of the S1SP in endothelial and organ injury in
COVID-19 patients.
The S1SP is capable of eliciting endothelial inflammation
and brain–blood barrier dysfunction (Buzhdygan et al.,
2020), and we recently demonstrated that it can disturb
human lung microvascular endothelial barrier function
(Biancatelli et al., 2021).
Even though more than 750 clinical trials were initiated in
2020, only few interventions have shown promise (Recovery
Collaborative Group et al., 2020). Thus, it is important to
keep investigating the potential countermeasures that can block
COVID-19-related endothelial dysfunction and ARDS.
Heat shock proteins (HSPs) are a family of chaperones that
assist a large number of “client proteins” in folding, stabilization,
and, if irreversibly damaged, degradation (Hoter et al., 2018).
HSPs participate in the stress response and are actively involved
in stabilizing pathways leading to inflammation (Craig, 1985).
HSP90 is critically involved in the pathogenesis of acute lung
injury and endothelial dysfunction, and its inhibition represents
an intriguing therapeutical approach (Antonov et al., 2008;
Barabutis, 2020).
Thus, we investigated the potential mechanisms responsible
for SP-mediated activation and barrier dysfunction in
human microvascular endothelial cells (HMVEC) and the
potential beneficial effects of pre- or post-treatment with
HSP90 inhibitors.
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MATERIALS AND METHODS
Reagents
Red protein G affinity beads, RIPA buffer, and protease inhibitor
cocktail were purchased from Sigma-Aldrich Corporation (St.
Louis, MO). The HSP90 inhibitors, AUY-922 and AT13387,
were obtained from Selleck Chemicals (Houston, TX). The BCA
Protein Assay Kit was purchased from Pierce Co. (Rockford,
IL), and Western blot membranes were purchased from GE
Healthcare (Chicago, IL). All antibodies used in Western blots
and immunoprecipitation have published immunospecificity
data available online. Rabbit anti-AKT, anti-phospho AKT, antiIKBα, anti-phospho IKBα, anti-STAT3, anti-phospho STAT3,
anti-VE-cadherin, anti-occludin, anti-cofilin, and anti-phospho
cofilin were purchased from Cell Signaling Technology (Danvers,
MA). Mouse monoclonal anti-β-actin and anti-p53 (P8999)
were purchased from Sigma-Aldrich Corporation, and secondary
IRDye 800CW goat anti-rabbit (926-32211) and IRDye 680RD
goat anti-mouse (926-68070) were purchased from LI-COR
Biosciences (Lincoln, NE). For SDS-PAGE, Protogel (30%
acrylamide mix) and TEMED were purchased from National
Diagnostics (Atlanta, GA), Tris-HCl buffer was purchased from
Teknova (Hollister, CA), 10% SDS and ammonium persulfate
were purchased from Thermo Fisher Scientific, and protein dualcolor standards and tricine sample buffer were purchased from
Bio-Rad Laboratories.

Cell Culture
In-house harvested human lung microvascular endothelial cells
(HLMVEC) were maintained in M199 media supplemented
with 20% FBS and antibiotics/antimycotics as described earlier
(Catravas et al., 2010).

Endothelial Barrier Function
Human lung microvascular endothelial cells were grown on
electrode arrays (8W10E +), and endothelial barrier integrity
was estimated by the electric substrate impedance sensing
(ECIS) method, using an ECIS model 1600R ζθ from Applied
Biophysics. Experiments were conducted when a stable resistance
was maintained above 800  as we have previously published
(Colunga Biancatelli et al., 2021). The single time frequency (SFT)
mode was selected at 4,000 Hz and at an interval time of 600 s.
Experiments were performed in triplicate and repeated at least 3
times. Resistance values were collected and normalized for each
well’s value at t = 0. Data are presented as means (± SEM).

Protein Isolation and Western Blots
Confluent HLMVEC cultured in 100 mm Petri dishes were
exposed to S1SP and/or HSP90 inhibitors or vehicles. For timecourse analyses, cells were incubated with 20 nM S1SP for 4, 6, or
12 h. For pretreatment studies, cells were incubated with HSP90
inhibitors (e.g., 2 µM AUY-922, AT13387, or vehicle) for 4 h
followed by 20 nM S1SP for an additional 4 h. For post-treatment
studies, cells were exposed to 20 nM S1SP for 4 h and then treated
with HSP90 inhibitors (e.g., 2 µM AUY-922, AT13387, or vehicle)
for 4 h. At the end of the experiment, dishes were placed on
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ice and washed 2 times with ice-cold PBS. PBS was removed
and ice-cold lysis buffer was added (RIPA, protease inhibitor
cocktail 1:100). Cells were then scraped, and the cell suspension
was transferred to a microcentrifuge tube. Tubes were retained at
4◦ C for 15 min under continuous agitation and spun for 10 min
at 14,000 rpm, the pellet was discarded, and the supernatant
transferred into new tubes. Proteins were quantified by BCA
protein assay, and tricine buffer with 2% 2-mercaptoethanol was
added at 1:1 ratio. Proteins were denaturated by boiling at 100◦ C
for 10 min, and protein lysates were subjected to SDS-PAGE
electrophoresis in 12% sodium dodecyl sulfate Tris-HCl gels.
Proteins were transferred onto nitrocellulose membranes and
blocked for 1 h at room temperature with 5% non-fat dry milk
in Tris-buffered saline containing 0.1% Tween 20. Membranes
were incubated overnight at 4◦ C with specific antibodies, washed
4 times, and incubated for 1 h at room temperature with the
appropriate peroxidase-conjugated secondary antibody. Bands
were detected by digital fluorescence imaging (LI-COR Odyssey
CLx). Densitometric evaluation of the bands was made using
ImageJ software (National Institutes of Health, Bethesda, MD).
β-actin was used to normalize loading differences.

RESULTS
SARS-CoV-2 S1SP Provokes a Time- and
Dose-Dependent Endothelial Barrier
Dysfunction
Human lung microvascular endothelial cells were grown on
810WE + arrays until a stable resistance was achieved (> 800
). S1SP elicited a fast and concentration-dependent decrease
in transendothelial electrical resistance (TER) (Figure 1A), while
the intact SP elicited a delayed and much milder decrease
(Figure 1B). As shown in Figure 1C, quantification of the
percentage decrease in TER confirms time- and concentrationdependent relationships and demonstrates that the effect of 50
nM SP was equivalent to that of 5 nM S1SP, i.e., that HLMVEC
were 10x more sensitive to S1SP than to SP. Analysis of ACE2
expression in HLMVEC displayed no significant changes after
exposure to S1SP (Figure 1D).

Subunit 1 of the SARS-CoV-2 Spike
Protein Induces Endothelial Activation
and Dysfunction

Immunocytochemistry

We investigated endothelial dysfunction after the exposure of
cells to 20 nM S1SP. S1SP evoked robust inflammation mediated
by early activation of STAT3 and NF-κB (Figure 2A). S1SP
also increased time-dependently the activation (phosphorylation)
of protein kinase B (AKT) (Figure 2A). We then analyzed
changes in cytoskeletal rearrangements and the expression
of junctional proteins. HLMVEC exposed to S1SP displayed
dephosphorylation of cofilin and reduced expression of occludin
and VE-cadherin (Figure 2B).

Round glass coverslips (Thermo Fisher Scientific) were placed
in 12-well plates, soaked in 70% ethanol for 15 min, and dried
under the hood. The cover glasses inside the plate’s wells were
covered with 1 ml of 0.2% gelatin and incubated at 37◦ C for
30 min. Excess gelatin was aspirated, and then 500 µl of the
cell suspension containing 6 × 105 HLMVEC was placed on
top. Coverslips with 75–90% confluent HLMVEC were fixated in
4% paraformaldehyde in PBS for 10 min, washed 3 times, then
subjected to permeabilization with 0.1% Triton-X 100 in TBS
for 10 min, and subsequently triple-washed in PBS. Cells were
blocked with 5% BSA in 0.1% TWEEN overnight at 4◦ C. On
the following day, coverslips were moved to a wet camera and
incubated with VE-cadherin antibody (Abcam, 1:50 dilution) in
blocking buffer at 4◦ C for 24 h. After washing 5 times in PBS,
secondary incubation was carried out with Alexa Fluor 488 goat
anti-rabbit antibody (Thermo Fisher Scientific, dilution 1:500)
in the dark at RT for 1 h and then washed 5 times. F-actin
was visualized with Texas Red-X phalloidin (Life Technologies,
diluted 1:300). At the counterstaining stage, cells were incubated
with 300 µM DAPI for 5 min in the dark. One drop of mounting
media (ProLong Gold, Thermo Fisher Scientific) was added on
pre-cleaned microscope slides (Superfrost Plus, Thermo Fisher
Scientific) and placed over the top of the coverslips facing
down, extra PBS was removed from the edges, and final slides
were placed in the dark at RT for overnight drying. Confocal
microscopy analysis was performed with an Olympics Fluoview
FV10i, and pictures were analyzed with ImageJ software (NIH).

HSP90 Inhibitors Prevent Subunit 1 of
the SARS-CoV-2 Spike Protein-Induced
Endothelial Barrier Dysfunction
We then investigated the ability of two chemically distinct
HSP90 inhibitors, namely, AUY-922 and AT13387, to prevent
S1SP-mediated injury. A 4-h pretreatment with either AUY922 or AT13387 (2 µM) completely prevented S1SP-induced
hyperpermeability (Figure 3A). Pretreatment with AUY-922
or AT13387 also prevented AKT and IKBα phosphorylation
(activation) (Figure 3B) and loss of integrity of the monolayer,
eliminated wide gap formation, and maintained the expression of
VE-cadherin (Figure 3C).

HSP90 Inhibitors Repair Subunit 1 of the
SARS-CoV-2 Spike Protein-Induced
Endothelial Activation and Barrier
Dysfunction

Statistical Analysis

We also investigated whether post-treatment with HSP90
inhibitors could repair S1SP-induced endothelial barrier
dysfunction and activation. HLMVEC seeded on gold electrodes
were exposed to 20 nM S1SP for 5 h, at which time 2 µM AUY922 or AT13387 or vehicle was added. Post-treatment with either
AT13387 or AUY-922 completely restored endothelial barrier

Statistical significance of differences among groups was
determined by one- or two-way ANOVA followed by Tukey’s
post hoc or Bonferroni’s test using GraphPad Prism Software
(GraphPad Software, San Diego, CA, United States). Differences
among groups were considered significant at p < 0.05.
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FIGURE 1 | Barrier dysfunction of human lung microvascular endothelial cells (HLMVEC) exposed to SARS-CoV-2 intact spike protein (SP) or to subunit 1 (S1SP).
(A) Changes in transendothelial electrical resistance (TER) of HLMVEC after exposure to vehicle or different concentrations of S1SP (5–50 nM). (B) Changes in TER
of HLMVEC after exposure to vehicle or different concentrations of SP (10–50 nM). (C) Percentage decrease in TER at different time points after S1SP or SP. (D)
Expression of ACE2 in lysates of HLMVEC exposed to S1SP for 4 h. Data represent means ± SEM; n = 3–5; ***p < 0.001; ****p < 0.0001 between groups, 2-way
ANOVA and Bonferroni’s post-test (A,B), or 1-way ANOVA and Tukey’s test (C,D).

alveolar-capillary structure is involved during SARS-CoV-2
infection as reflected in ventilation/perfusion mismatch and in
the various clinical features of near-normal and reduced lung
compliance (Santamarina et al., 2020).
We investigated if subunit 1 of S1SP, released in the
extracellular or vascular compartment after its interaction with
ACE2, could participate in pulmonary endothelial inflammation
and barrier dysfunction. In this study, the intact SP elicited
a minor and delayed endothelial dysfunction response, in
agreement with studies showing that endothelial cells are
resistant to intact SARS-CoV-2 infection (Ahmetaj-Shala et al.,
2020). This is not surprising, as the SP requires a two-step
cleavage by furin and/or furin-like proteases. In this study,
we focused on understanding if the S1SP, released after SP
cleavage during cell infection, participates in eliciting a local
inflammatory response.
Our findings suggest that S1SP exhibits high biological activity
and is capable of damaging, in a time- and concentrationdependent manner, the integrity of HLMVEC. This was reflected
in the activation of inflammatory pathways STAT3 and NF-κB;
the phosphorylation of AKT and cofilin; and the loss of critical
junctional proteins, occludin, and VE-cadherin.
The S1SP does not affect the constitutive expression of
ACE2; similarly, various authors have provided evidence of
a non-receptor-mediated pathway of S1SP-mediated injury.

function after S1SP injury (Figure 4A). Furthermore, both
AUY-922 and AT13387 repaired the S1SP-mediated activation of
IKBα and AKT (Figure 4B).

DISCUSSION
Severe
acute
respiratory
syndrome
coronavirus-2
pathophysiology is not completely understood. COVID-19
patients develop atypical features of acute respiratory distress
syndrome (ARDS) (Gattinoni et al., 2020a,b). These particular
phenotypes exhibit reduced responsiveness to standard
treatments, and high-flow nasal cannula and non-invasive
ventilation are preferred over a more invasive management even
in severe cases (Grieco et al., 2021; Shoukri, 2021).
The alveolar type II cells are not the sole targets of SARSCoV-2-mediated injury. COVID-19 patients display increased
coagulability, with autopsy findings of microthrombi in lung
capillaries, which are considered the major determinants
of death (McFadyen et al., 2020; Chen and Pan, 2021).
Endothelial cells exposed to the spike protein display increased
expression of adhesion molecules, and spike protein similarly
promotes platelet activation leading to thrombophilia observed
in COVID-19 (Buchrieser et al., 2020; Bussani et al., 2020;
Buzhdygan et al., 2020; Passariello et al., 2021). Thus, the entire
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FIGURE 2 | Activation of HLMVEC exposed to 20 nM of S1SP for 4–12 h. (A) Western blot analysis of AKT, IKBα, and-STAT3 phosphorylation; (B) cofilin
phosphorylation and expression of occludin and VE-cadherin. Activated proteins are expressed as the ratio of phosphorylated to total protein. Data represent
means ± SEM; n = 3–4; *p < 0.05; **p < 0.01; ***p < 0.001 between groups, 1-way ANOVA and Tukey’s post hoc test.

Spike protein can activate macrophages via Toll-like receptor
2 through NF-κB activation and the consequent release of
IL-8, IL-6, and TNFα (Dosch et al., 2009). The non-receptormediated injury by S1SP is also demonstrated by its ability
to permeabilize membranes and disrupt lipid bilayers (Asandei
et al., 2020). Macrophages, exposed to the intact spike protein
(SP), display increased levels of reactive oxygen species (ROS)
and monocyte chemoattractant protein-1 (MCP-1) and, at high
SP concentrations (100 nM), caspase activation and apoptosis
(Barhoumi et al., 2021). Endothelial cells, transfected with a
pseudovirus expressing the spike protein, displayed impaired
endothelial function and NO synthase (eNOS) activity that
reduced endothelium-dependent vasodilation in response to
acetylcholine (Lei et al., 2021). This, in addition to the
spike protein subunits 1- and 2-mediated overexpression

Frontiers in Physiology | www.frontiersin.org

of intracellular adhesion molecule-1 (ICAM-1) and vascular
adhesion protein-1 (VCAM-1), suggests a direct role of the SP in
eliciting a pro-inflammatory and pro-thrombotic vascular disease
(Buzhdygan et al., 2020).
Accumulating evidence supports the notion that HSP90
inhibitors may serve as a novel, broad-targeted approach for
the management of lung injury and ARDS. HSP90 stabilizes
multiple proteins and thus optimizes or activates various crucial
intracellular inflammatory pathways. When HSP90 is inhibited,
its client proteins become unstable and degraded, with the result
of inefficient or absent inflammatory signaling. Pretreatment or
post-treatment with HSP90 inhibitors modulates the severity
of lung injury and prevents mortality after exposure to LPS
(Chatterjee et al., 2007). This is due, at least in part, to the fact
that HSP90 interacts with NF-κB signaling at multiple levels: it
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FIGURE 3 | Pretreatment with HSP90 inhibitors prevented S1SP-mediated endothelial dysfunction. (A) 4 h of pretreatment with either HSP90 inhibitor (2 µM
AUY-922 or AT13387), but not vehicle, prevented S1SP-mediated changes in transendothelial resistance. (B) Western blotting of activated (phosphorylated) and
total AKT and IKBα from HLMVEC incubated for 4 h with HSP90 inhibitors before 4 h exposure to S1SP. (C) Immunostaining for VE-cadherin, F-actin, and DAPI of
cells incubated 4 h with HSP90 inhibitors (2 µM) and subsequently exposed for 4 h to 20 nM S1SP. Means ± SEM; n = 3–4; *p < 0.05; **p < 0.01; ***p < 0.001
between groups, 1-way ANOVA and Tukey’s post hoc test.
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FIGURE 4 | Posttreatment with HSP90 inhibitors restored S1SP-mediated endothelial activation and barrier dysfunction. (A) Post-treatment with either of the two
HSP90 inhibitors (2 µM AUY-922 or AT13387) following 5 h of exposure to 20 nM S1SP repaired changes in TER. (B) Western blot analysis of activated
(phosphorylated) and total AKT and IKBα in HLMVEC incubated for 5 h with S1SP followed by 4 h treatment with HSP90 inhibitors. Means ± SEM; n = 3–4;
*p < 0.05; **p < 0.01; ***p < 0.001 between groups, 1-way or 2-way ANOVA and Tukey’s or Bonferroni’s post hoc test.

regulates NF-κB by inducing kinase (NIK) (Qing et al., 2007)
and together with HSP70 modulates IKK complex altering NFκB activation (Salminen et al., 2008). Additionally, our group
has demonstrated two mechanisms of HSP90/NF-κB interaction:
the first mechanism is mediated by HSP90 binding to type2 sirtuin histone deacetylase (Thangjam et al., 2016), and the
second mechanism is mediated by HSP90 binding to the coactivator cAMP response element-binding protein required for
RNA transcription (Thangjam et al., 2014).
In this study, the two HSP90 inhibitors, namely, AT13387 and
AUY-922, effectively modulated the S1SP-mediated activation
of IKBα, both when administered as pretreatment or as posttreatment.
HSP90 inhibitors display the ability to prevent endothelial
activation at multiple levels. HSP90 inhibitors prevent the
activation of p53 and RhoA and regulate the balance
between phospho- and pan-cofilin, an effect mediated by
LIM kinase 1 (LIMK1) (Li et al., 2006). The HSP90 inhibitor
Frontiers in Physiology | www.frontiersin.org

17-DMAG modulates the phosphorylation of myosin light
chain reducing LPS-mediated cytoskeletal rearrangements in
bovine endothelial cells (Barabutis et al., 2019), and, more
recently, we showed that AUY-922 was highly beneficial
in an HCl model of endothelial dysfunction (Colunga
Biancatelli et al., 2021). In this study, the use of two different
third-generation HSP90 inhibitors ameliorated the loss of
intercellular VE-cadherin reducing S1SP-mediated loss of
integrity and hyperpermeability.
The novel approach with HSP90 inhibitors has proven
to be beneficial in the treatment of different models of
lung injury, including the spike protein subunit 1-mediated
endothelial dysfunction. HSP90 inhibitors could represent a
novel approach for ALI, and ARDS can reduce capillary
permeability during inflammation and prevent leaks into the lung
parenchyma and alveolar space. Additional data are required
for further experimentation of HSP90 inhibitors in in vivo
models of COVID-19.
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